Cargando…

Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasis

BACKGROUND: Infections with Strongyloides stercoralis belong to the most neglected helminth diseases, and research and development (R&D) efforts on novel drugs are inadequate. METHODS: A commercially available library containing 1600 FDA-approved drugs was tested in vitro against Strongyloides r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keiser, Jennifer, Häberli, Cécile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705154/ https://www.ncbi.nlm.nih.gov/pubmed/34949209 http://dx.doi.org/10.1186/s13071-021-05117-2

Ejemplares similares

Strongyloides ratti: In Vitro and In Vivo Activity of Tribendimidine
por: Keiser, Jennifer, et al.
Publicado: (2008)

Investigations for the Possible Use of a Monoclonal Antibody Produced against Strongyloides ratti Antigen as an Immunodiagnostic Reagent for Active Strongyloidiasis
por: MAHMUDA, Aliyu, et al.
Publicado: (2018)

Strongyloides ratti and S. venezuelensis – rodent models of Strongyloides infection
por: VINEY, MARK, et al.
Publicado: (2017)

Density-dependent immune responses against the gastrointestinal nematode Strongyloides ratti
por: Bleay, Colin, et al.
Publicado: (2007)

Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
por: Planer, Joseph D., et al.
Publicado: (2014)

Immunological Responses Elicited by Different Infection Regimes with Strongyloides ratti
por: Paterson, Steve, et al.
Publicado: (2008)

Clinical value of serology for the diagnosis of strongyloidiasis in travelers and migrants: A 4-year retrospective study using the Bordier IVD(®) Strongyloides ratti ELISA assay
por: Autier, Brice, et al.
Publicado: (2021)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
por: Panic, Gordana, et al.
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Basophils are dispensable for the establishment of protective adaptive immunity against primary and challenge infection with the intestinal helminth parasite Strongyloides ratti
por: Reitz, Martina, et al.
Publicado: (2018)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

RNAi-mediated knockdown of daf-12 in the model parasitic nematode Strongyloides ratti
por: Dulovic, Alex, et al.
Publicado: (2019)

Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections
por: Keiser, Jennifer, et al.
Publicado: (2016)

In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria
por: Peyclit, Lucie, et al.
Publicado: (2022)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Identification of FDA-Approved Drugs with Activity against Stationary Phase Bartonella henselae
por: Li, Tingting, et al.
Publicado: (2019)

Correction: RNAi-mediated knockdown of daf-12 in the model parasitic nematode Strongyloides ratti
por: Dulovic, Alex, et al.
Publicado: (2020)

The parasitic nematode Strongyloides ratti exists predominantly as populations of long-lived asexual lineages
por: Cole, Rebecca, et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

Epidemiology of strongyloidiasis determined by parasite-specific IgG detections by enzyme-linked immunosorbent assay on urine samples using Strongyloides stercoralis, S. ratti and recombinant protein (NIE) as antigens in Northeast Thailand
por: Eamudomkarn, Chatanun, et al.
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Virtual Screening of FDA-Approved Drugs against LasR of Pseudomonas aeruginosa for Antibiofilm Potential
por: Sadiq, Suhaib, et al.
Publicado: (2020)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
por: Cowan, Noemi, et al.
Publicado: (2015)

FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
por: Mostafa, Ahmed, et al.
Publicado: (2020)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022)

A microarray analysis of gene expression in the free-living stages of the parasitic nematode Strongyloides ratti
por: Thompson, Fiona J, et al.
Publicado: (2006)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
por: Ginex, Tiziana, et al.
Publicado: (2021)

Computational models identify several FDA approved or experimental drugs as putative agents against SARS-CoV-2
por: Bobrowski, Tesia, et al.
Publicado: (2020)

MEMBRANE FRACTIONS FROM Strongyloides venezuelensis IN THE IMMUNODIAGNOSIS OF HUMAN STRONGYLOIDIASIS
por: Corral, Marcelo Andreetta, et al.
Publicado: (2015)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Transposon-mediated Chromosomal Integration of Transgenes in the Parasitic Nematode Strongyloides ratti and Establishment of Stable Transgenic Lines
por: Shao, Hongguang, et al.
Publicado: (2012)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
por: Feng, Jie, et al.
Publicado: (2014)

Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
por: Risner, Kenneth, et al.
Publicado: (2019)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Park, Su-Jin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9gk4983bqkn3qod8cm610ti4kd